Sotrovimab utility in doubt as BA.2 subvariant dominates in COVID-19

Experts are poised to change advice to doctors just as the TGA considers a bid to 'up' the dose

Most patients with COVID-19 in Australia now have the BA.2 subvariant of Omicron, posing a dilemma over the use of the monoclonal antibody sotrovimab, doctors have been told.

Associate Professor Bridget Barber.
Associate Professor Bridget Barber.

Infectious diseases physician Associate Professor Bridget Barber told a federal Department of Health webinar on Thursday night that experts were developing new